447 Liver histology in chronic hepatitis B patients after 1 year of treatment with pegylated interferon alpha-2B in combination with lamivudine or placebo

Combination Therapy of Pegylated Interferon alpha 2b (PegIFN) and Adefovir Dipivoxil (ADV) in Chronic Hepatitis B (CH-B) Patients Reduces the Reservoir of Transcriptionally Active cccDNA and Hepatitis B Surface Antigen (HBsAg)

Zeitschrift für Gastroenterologie ◽

10.1055/s-2005-862299 ◽

2005 ◽

Vol 43 (01) ◽

Author(s):

F Metzler ◽

K Wursthorn ◽

B Zoellner ◽

P Buggisch ◽

M Zankel ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Combination Therapy ◽

Chronic Hepatitis B ◽

Interferon Alpha ◽

Adefovir Dipivoxil ◽

Hepatitis B Surface Antigen ◽

Pegylated Interferon ◽

Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China

World Journal of Pediatrics ◽

10.1007/s12519-019-00303-w ◽

2019 ◽

Vol 15 (6) ◽

pp. 595-600 ◽

Cited By ~ 3

Author(s):

Yao Hu ◽

Ying-Zi Ye ◽

Li-Jing Ye ◽

Xiao-Hong Wang ◽

Hui Yu

Keyword(s):

Chronic Hepatitis ◽

Cohort Study ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Interferon Alpha ◽

Real Life ◽

Pegylated Interferon ◽

Efficacy And Safety ◽

51 Early hepatitis B viral dynamics and end of treatment virological response (ETVR) in chronic hepatitis B/ HBeAg (−) patients receiving 1528 0689V 2 pegylated interferon alpha-2b and/or lamivudine

Journal of Hepatology ◽

10.1016/s0168-8278(06)80516-7 ◽

2006 ◽

Vol 44 ◽

pp. S192

Author(s):

T. Vassiliadis ◽

V. Sypsa ◽

K. Mimidis ◽

N.C. Tassopoulos ◽

D. Chrysagis ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Interferon Alpha ◽

Virological Response ◽

Pegylated Interferon ◽

Viral Dynamics ◽

Interferon Alpha 2B ◽

End Of Treatment

48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection

Alimentary Pharmacology & Therapeutics ◽

10.1111/j.1365-2036.2006.02887.x ◽

2006 ◽

Vol 23 (8) ◽

pp. 1171-1178 ◽

Cited By ~ 7

Author(s):

C.-K. HUI ◽

L. S. W. LAI ◽

P. LAM ◽

H.-Y. ZHANG ◽

T.-T. FUNG ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Interferon Alpha ◽

Pegylated Interferon ◽

Hepatitis B Infection ◽

Hepatitis B E Antigen ◽

Chronic Hepatitis B Infection ◽

A viral kinetic study using pegylated interferon alpha 2b and lamivudine in naive patients with HBeAg(−)/I-BV-DNA(+) chronic hepatitis B: preliminary results

Journal of Hepatology ◽

10.1016/s0168-8278(02)80330-0 ◽

2002 ◽

Vol 36 ◽

pp. 94 ◽

Cited By ~ 1

Author(s):

Vana Sypsa ◽

Nicolaos C. Tassopoulos ◽

Dimitrios Chrysagis ◽

Konstantinos Mimidis ◽

Themistoklis Vassiliadis ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Kinetic Study ◽

Chronic Hepatitis B ◽

Interferon Alpha ◽

Pegylated Interferon ◽

Preliminary Results ◽

Interferon Alpha 2B ◽

Viral Kinetic

Ulcerative colitis triggered by pegylated interferon alpha-2b in a patient with chronic hepatitis B: A case report and literature review

Liver Research ◽

10.1016/j.livres.2021.04.001 ◽

2021 ◽

Author(s):

Zhishuo Mo ◽

Jian Tang ◽

Zeqian Wu ◽

Dabiao Chen ◽

Dongying Xie ◽

...

Keyword(s):

Ulcerative Colitis ◽

Chronic Hepatitis ◽

Case Report ◽

Hepatitis B ◽

Literature Review ◽

Chronic Hepatitis B ◽

Interferon Alpha ◽

Pegylated Interferon ◽

The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation

Alimentary Pharmacology & Therapeutics ◽

10.1111/j.1365-2036.2005.02453.x ◽

2005 ◽

Vol 21 (9) ◽

pp. 1163-1171 ◽

Cited By ~ 41

Author(s):

M. Zonneveld ◽

H. J. Flink ◽

E. Verhey ◽

H. Senturk ◽

S. Zeuzem ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Dose Reduction ◽

Chronic Hepatitis B ◽

Interferon Alpha ◽

Predictive Factors ◽

Pegylated Interferon ◽

Treatment Discontinuation ◽

NKp30+ NK cells are associated with HBV control during pegylated-interferon-alpha-2b therapy of chronic hepatitis B

Scientific Reports ◽

10.1038/srep38778 ◽

2016 ◽

Vol 6 (1) ◽

Cited By ~ 7

Author(s):

Xiaokun Shen ◽

Binqing Fu ◽

Yanyan Liu ◽

Chuang Guo ◽

Ying Ye ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Nk Cells ◽

Chronic Hepatitis B ◽

Interferon Alpha ◽

Pegylated Interferon ◽

Sa1313 Sequential Nuc Therapy Following Pegylated Interferon-Alpha Exposure Restores Innate Immune Responses Conferring a Treatment Advantage Over Nuc Monotherapy in Chronic Hepatitis B

Gastroenterology ◽

10.1016/s0016-5085(14)60915-x ◽

2014 ◽

Vol 146 (5) ◽

pp. S-260

Author(s):

Upkar S. Gill ◽

Dimitra Peppa ◽

Lorenzo Micco ◽

Harsimran D. Singh ◽

Graham Foster ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Immune Responses ◽

Chronic Hepatitis B ◽

Interferon Alpha ◽

Pegylated Interferon ◽

Innate Immune ◽

Innate Immune Responses ◽

Pegylated Interferon Alpha

Assessment of Quality of Life of Patients with Chronic Hepatitis B and C Treated with Pegylated Interferon-alpha

Viral Hepatitis Journal ◽

10.4274/vhd.2017.0016 ◽

2018 ◽

Vol 24 (2) ◽

pp. 25-42

Author(s):

Handan ALAY ◽

Kemalettin ÖZDEN ◽

Serpil EROL ◽

Neslihan ÇELİK ◽

Emine PARLAK ◽

...

Keyword(s):

Quality Of Life ◽

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Interferon Alpha ◽

Pegylated Interferon ◽

Pegylated Interferon Alpha